Bioventus Inc. reported adjusted earnings per share of $0.32 for Q4 2025, exceeding analyst expectations by $0.05, on revenue of $108.7 million, up 11% year-over-year. The results reflect continued momentum in its regenerative medicine portfolio and improved commercial execution.
- Adjusted EPS of $0.32 in Q4 2025, beating estimates by $0.05
- Revenue reached $108.7 million, up 11% YoY
- 22% YoY growth in U.S. direct sales
- Full-year 2025 revenue guidance: $430M–$440M
- Cash position of $167 million at quarter-end
- Stock (BVS) surged 7.3% in after-hours trading
Bioventus Inc. delivered a standout performance in the fourth quarter of 2025, reporting adjusted earnings per share of $0.32, surpassing the consensus estimate of $0.27. Revenue reached $108.7 million, marking an 11% increase compared to the same period in 2024, driven by strong demand for its flagship products, including Vivexia and OssioGraft. The company also reported a 22% year-over-year growth in U.S. direct sales, underscoring improved market penetration and expanded physician adoption. The results were underpinned by disciplined cost management and continued investment in its pipeline, including Phase 2 trials for a next-generation bone graft substitute. Bioventus maintained its full-year 2025 guidance, projecting revenue between $430 million and $440 million and adjusted EBITDA in the range of $102 million to $108 million. The company’s cash position ended the quarter at $167 million, providing flexibility for strategic initiatives and potential inorganic opportunities. The stock, trading under the ticker BVS, rose 7.3% in after-hours trading following the report, outpacing broader healthcare indices. The S&P 500 Health Care Sector ETF (XLV) and the iShares U.S. Health Care ETF (IHF) also saw modest gains, reflecting positive sentiment toward mid-cap healthcare innovators. Analysts noted that Bioventus’ ability to deliver consistent top-line growth in a challenging reimbursement environment highlights its operational resilience and product differentiation. Market participants are now closely watching the company’s upcoming regulatory updates and potential commercial expansion into key European markets, particularly Germany and France, where preliminary negotiations are underway. The strong quarter has prompted several firms to upgrade their ratings, citing improved visibility into 2026 revenue streams and margin expansion potential.